Navigation Links
LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Date:9/1/2009

BARCELONA, Spain, Sept. 1 /PRNewswire/ -- New data presented today showed that in patients treated with LIVALO (pitavastatin), high-density lipoprotein cholesterol (HDL-C) concentrations increased, and nearly three-fourths of patients attained low-density lipoprotein cholesterol (LDL-C) targets, with results sustained over 52 weeks. Additionally, LIVALO was found to have comparable efficacy to atorvastatin and simvastatin, as measured by reduction in LDL-C from baseline. The Phase III data were presented at the European Society of Cardiology Congress (ESC) in Barcelona, Spain.

"These studies confirm that the efficacy of LIVALO is comparable to other commonly used statins, and that it is an effective and well tolerated long-term treatment option for patients," said Leiv Ose, M.D. Ph.D., Rikshospitalet University Hospital, Norway, and study investigator. "With many patients not reaching LDL-C targets with current statin therapies due to a number of factors, including noncompliance and the risk for drug-drug interactions, there is a need for a statin that has the potential to improve long-term treatment."

The primary objective of the two Phase III, double-blind, active-controlled studies was to demonstrate non-inferiority of LIVALO to atorvastatin and simvastatin, as measured by the reduction of LDL-C. Secondary objectives of the study were to assess National Cholesterol Education Program (NCEP) and European Atherosclerosis Society (EAS) LDL-C target attainment, other lipid and lipoprotein fractions, safety and tolerability. An open-label extension study was also conducted to assess the long-term safety and tolerability of LIVALO 4 mg once daily for up to 52 weeks.

"Data from these pivotal, Phase III studies show that LIVALO has a robust efficacy, safety and tolerability profile, and in terms of LDL-C reduction, stands up to atorvastatin and simvastatin at usual therapeutic do
'/>"/>

SOURCE Kowa Company Ltd., Kowa Pharmaceuticals America, Inc., and Kowa Research Institute, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
2. Noteworthy Medical Systems Demonstrates National Health Information Network (NHIN) Interoperability
3. Recently Published Study Demonstrates Pharmacokinetic Advantages of ENDOMETRIN(R) Over Crinone(R) for Progesterone Supplementation
4. Advanced Life Sciences Restanza Demonstrates Efficacy in Treating Anthrax Infection
5. Survey Demonstrates Marin County Residents Support Locally Owned and Operated Marin General Hospital
6. EVEREST Data Demonstrates Acute Reduction of Mitral Regurgitation Without Procedural Mortality in Patients Treated With the MitraClip(R) Therapy
7. VivaGel(R) Demonstrates Anti-HIV and Herpes Activity Following Human Administration
8. CAeHC Demonstrates NHIN-enabled Gateways Among Five California Health Information Exchanges
9. Study demonstrates the anti-inflammatory properties of pine bark extract
10. Study Demonstrates the Anti-Inflammatory Properties of Pine Bark Extract on Inflammatory Mediators COX-2 and 5-LOX
11. Analysis of drug-eluting stents data demonstrates safety, efficacy in on-and-off-label use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 25, 2014 Product liability lawsuits filed ... recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in ... Order issued in the U.S. District Court, Northern District ... an open conference on January 7, 2015, at the ... in West Palm Beach, Florida. The Conference is scheduled ...
(Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... with complex chronic illnesses can receive effective, less expensive care ... easy access to a team of dedicated health care professionals, ... become seriously ill and need either hospitalization or a trip ... enhanced medical home clinic at the University of Texas in ...
(Date:12/25/2014)... tries its best to translate the experience of dress ... introduced its new collection of 2015 prom dresses, and ... prom outfits are guaranteed to contain the perfect designs ... designed for 2015. Anyone who wants to buy ... before Jan. 26, 2015, the deadline of the promotion. ...
(Date:12/25/2014)... Rosa, CA (PRWEB) December 25, 2014 ... department visits and 2 million hospital admissions across the ... and Prevention ). The CDC’s National Hospital Ambulatory ... departments through a survey conducted in 2010. They estimated ... department visits that resulted in a primary diagnosis of ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... is pleased to announce the opening of attendee registration ... Technology Exposition and Conference. This year,s event will be ... Stephens Convention Center in Rosemont, Illinois. OMTEC is the ... industry professionals involved in all facets of the supply ...
... year by a Cornell researcher add to growing evidence that ... of other fruits and vegetables -- can help keep the ... in the Journal of Agricultural and Food Chemistry ... and a member of Cornell,s Institute for Comparative and Environmental ...
... manifested in a variety of tissues and cancer cells ... being studied as a novel treatment. The PPAR-gamma ligand ... differentiation, apoptotic induction, and changes in genes or proteins ... been some reports suggesting that stomach cancer cells manifest ...
... been used as the "gold standard" for the assessment of ... possible complications of this procedure, for both, the physician and ... not trivial one. So, scientists tend to introduce non-invasive methods ... to be published on February 7, 2009 in the ...
... researcher Dr. Daniel Von Hoff and his team at ... developing novel therapies for patients with pancreatic cancer. They ... vulnerability." Dr. Von Hoff provides case studies and ... promising discoveries and is changing the future of oncology ...
... wartime conditions, researchers say , , TUESDAY, Feb. 17 (HealthDay ... be exacerbated by combat conditions in Iraq and Afghanistan ... evacuated for treatment, a new report finds. , In ... for poor morale and combat ineffectiveness, the researchers noted ...
Cached Medicine News:Health News:OMTEC Registration Opens - Education for a Competitive Advantage in Orthopaedics 2Health News:In flurry of studies, researcher details role of apples in inhibiting breast cancer 2Health News:What is the suppressing effect of the PPAR-gamma ligands on stomach cancer cells? 2Health News:Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development 2Health News:Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development 3Health News:Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development 4Health News:Skin Woes Take Toll on U.S. Combat Troops 2Health News:Skin Woes Take Toll on U.S. Combat Troops 3
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... LEXINGTON, Mass. , Dec. 23, 2014 /PRNewswire/ ... GEVA ), a biopharmaceutical company developing therapeutic products ... European Medicines Agency (EMA) of the Marketing Authorization ... The EMA recently granted the company,s request for ... the EMA,s regulatory review time.   ...
(Date:12/24/2014)... Va. , Dec. 23, 2014  The ... diastolic blood pressure target for people with diabetes ... moderate or high doses of statins, in keeping ... management enacted by the American College of Cardiology ... are reflected in the most recent changes to ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... Sciences, Inc., a,privately held biopharmaceutical company developing ... BSI-401 inhibited pancreatic cancer,cell growth in vitro ... combination with,oxaliplatin. BSI-401 is BiPar,s second-generation product ... as PARP (poly-ADP-ribose polymerase) inhibitors. Researchers ...
... sleep apnea and sleep behavior,disorders, ROCHESTER, Minn., ... diagnosing and treating patients with a,variety of sleep ... at CHEST 2007, the annual meeting of the ... 20-25. The following are,brief summaries of select presentations., ...
Cached Medicine Technology:BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor 2Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 2Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 3Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 4
VG2 PLIF (Trapezoid) Posterior lumbar interbody fusion. Frozen preservation. Consists of two outer cortical planks, center cancellous plank, all from the same donor, held together by two press-fit co...
VG1 ALIF (Anterior Lateral) Anterior lumbar interbody fusion. Frozen freeze-dried preservation....
... Corlok Allografts are unique corticocancellous ... face and a unique Dovetail geometry ... adjacent vertebrae. Corlok Allografts are processed ... spinal allograft implants. Specially designed instruments ...
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Medicine Products: